Lfcr investors have opportunity to lead lifecore biomedical, inc. securities fraud lawsuit

New york , aug. 24, 2024 /prnewswire/ --  why: rosen law firm, a global investor rights law firm, reminds purchasers of securities of lifecore biomedical, inc. (nasdaq: lfcr) between october 7, 2020 and march 19, 2024, both dates inclusive (the "class period"), of the important september 27, 2024 lead plaintiff deadline. so what: if you purchased lifecore securities during the class period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
LFCR Ratings Summary
LFCR Quant Ranking